navan
/
Daily-Dose
mirror of https://github.com/navanchauhan/Daily-Dose.git
1
0
Fork 0
Code Issues Projects Releases Wiki Activity
Daily-Dose/archive-covid-19/13 March, 2021.html

218 lines
57 KiB
HTML
Raw Normal View History

Added daily report
2021-03-13 12:53:14 +00:00
<!DOCTYPE html>
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
<meta charset="utf-8"/>
<meta content="pandoc" name="generator"/>
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
<title>13 March, 2021</title>
<style type="text/css">
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
span.underline{text-decoration: underline;}
div.column{display: inline-block; vertical-align: top; width: 50%;}
</style>
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
<body>
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
<ul>
<li><a href="#from-preprints">From Preprints</a></li>
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
<li><a href="#from-pubmed">From PubMed</a></li>
<li><a href="#from-patent-search">From Patent Search</a></li>
</ul>
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
<ul>
<li><strong>Predictive and Causal Analysis of No-Shows for Medical Exams During COVID-19: A Case Study of Breast Imaging in a Nationwide Israeli Health Organization</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
“No-shows”, defined as missed appointments or late cancellations, is a central problem in healthcare systems. It has appeared to intensify during the COVID-19 pandemic and the nonpharmaceutical interventions, such as closures, taken to slow its spread. No-shows interfere with patients9 continuous care, lead to inefficient utilization of medical resources, and increase healthcare costs. We present a comprehensive analysis of no-shows for breast imaging appointments made during 2020 in a large medical network in Israel. We applied advanced machine learning methods to provide insights into novel and known predictors. Additionally, we employed causal inference methodology to infer the effect of closures on no-shows, after accounting for confounding biases, and demonstrate the superiority of adversarial balancing over inverse probability weighting in correcting these biases. Our results imply that a patient9s perceived risk of cancer and the COVID-19 time-based factors are major predictors. Further, we reveal that closures impact patients over 60, but not patients undergoing advanced diagnostic examinations.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.03.12.21253358v1" target="_blank">Predictive and Causal Analysis of No-Shows for Medical Exams During COVID-19: A Case Study of Breast Imaging in a Nationwide Israeli Health Organization</a>
</div></li>
<li><strong>THE NEGATIVE IMPACT OF The HOMININ’s DPP4 GENE INHERITED from NEANDERTHALS to PANDEMIC of COVID-19</strong> -
<div>
Background: According to preliminary sequences from 2010, 99.7% of the nucleotide sequences of the modern human and Neanderthal genomes are identical, compared to humans sharing around 98.8% of sequences with the chimpanzee. … In contrast, the difference between chimpanzees and modern humans is approximately 1,462 mtDNA base pairs. Materials and Methods: Neanderthal-inherited genetic material is found in all non-African populations and was initially reported to comprise 1 to 4 percent of the genome. This fraction was later refined to 1.5 to 2.1 percent. We had gone through many researches of Neanderthals affected gene flow in humans. Results: It is estimated that 20 percent of Neanderthal DNA currently survives in modern humans. Modern human genes involved in making keratin, a protein constituent of skin, hair, and nails, have especially high levels of introgression. For example, approximately 66% of East Asians contain a POUF23L variant introgressed from Neanderthals, while 70% of Europeans possess an introgressed allele of BNC2. Our finding shines a light on an enzyme called dipeptidyl peptidase4 (DPP4). Scientists already know the protein allows another coronavirus, which causes Middle Eastern respiratory syndrome (MERS), to bind to and enter human cells. The new analysis, of DPP4 gene variants among COVID-19 patients, suggests the enzyme also provides SARS-CoV-2 with a second door into our cells, along with its usual infection route via the angiotensin-converting enzyme 2 (ACE2) receptor on cell surfaces. Conclusion: Most Europeans, Asians, and Native Americans harbor a handful of genes from Neanderthals, up 1.8% to 2.6% of their DNA. Studies of ancient DNA in Neanderthal fossils have shown the hominin’s DPP4 gene subtly differs from the typical human one. Conclusion: The hominin’s DPP4 gene inherited from Neanderthals plays a major role in Immune System Disorders and Lower Immune response in many diseases. This gene plays a major role in affecting humans with COVID-19 and spreading it through the world. All humans contain this gene from 1 to 4 percent. East Asians, Europeans, Middle and south Americans conveys more, hence; native Africans contain less amounts of hominin’s DPP4 gene. Therefore; East Asians, Europeans, Middle and south Americans are prone to severe COVID-19.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/6fhz9/" target="_blank">THE NEGATIVE IMPACT OF The HOMININ’s DPP4 GENE INHERITED from NEANDERTHALS to PANDEMIC of COVID-19</a>
</div></li>
<li><strong>On the Neglected Shifting balance theory, Bateson–Dobzhansky–Muller model &amp; Quantum evolution plus the Role of Mitochondrial Membrane Potential (MMP) Impact on COVID-19</strong> -
<div>
Background: Approximately 80% of all viruses are RNA viruses and they contain their specific RNA helicases. Defective RNA helicases have been linked to infectious diseases (Viral Infections). Materials and Methods: The articles have gone through many types of research from the beginning of the epidemic of Coronaviruses through history and we introduced the neglected hypothesis of Shifting balance theory, Bateson–Dobzhansky–Muller model &amp; Quantum evolution. In the ancestral population, the genotype is AABB. When two populations become isolated from each other, new mutations can arise. In one population A evolves into a, and in the other B evolves into b. When the two populations hybridize it is the first time A and B interact with each other. When these alleles are incompatible, we speak of Dobzhansky–Muller incompatibilities plus the role of MMA in mitochondria in spreading SARS-CoV-19 through populations and the result of an infection in COVID-19. Results: In viruses specifically COVID-19, Ribosomal Frameshift is programmed to allows the virus to encode multiple types of proteins from the same mRNA. HIV-1 (human immunodeficiency virus), RSV (Rous sarcoma virus), and all types of influenza viruses use Ribosomal Frameshift. they rely on frameshifting to create a proper ratio of normal translation and trans-frame (encoded by frameshifted sequence) proteins. Notably, its use in viruses is primarily for compacting more genetic information into a shorter amount of genetic material. Conclusion: to find the genome sequence of COVID-19 we also used Nanopore sequencing that introduced and manufactured by Oxford scientists, due to differences in the action of infection in the host, we could not reach any results since the Novel Virus has not a stable genome (which is quite dynamic) since through our deep research, each virus contains its specific genome sequencing and we cannot claim that COVID-19 has one specific genome sequence like MERS-CoV, SARS-CoV or any types of viruses which has been discovered and contains their specific genome.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://osf.io/b5dr3/" target="_blank">On the Neglected Shifting balance theory, Bateson–Dobzhansky–Muller model &amp; Quantum evolution plus the Role of Mitochondrial Membrane Potential (MMP) Impact on COVID-19</a>
</div></li>
<li><strong>Commonly reported problems and coping strategies during the COVID-19 crisis: A survey of graduate and professional students</strong> -
<div>
Background: The COVID-19 crisis has introduced a variety of stressors, while simultaneously decreasing the availability of strategies to cope with stress. In this context, it could be useful to understand issues that people find most concerning and ways in which they cope with stress. In this study, we explored these questions with a sample of graduate and professional students. Method: Using open-ended assessments, we asked participants (n=305) to identify their biggest challenge or concern (“top problem”), their most effective way of handling stress (“effective strategy”), and their most common way of handling stress (“common strategy”). We applied thematic analysis and evaluated whether participants’ strategies corresponded with evidence-based practices (EBPs). Results: Participants frequently reported top problems relating to productivity (27% of sample), physical health (26%), and emotional health (14%). Distraction was the most frequently classified common strategy (43%), whereas behavioral activation was the most frequently identified effective strategy (50%). Participants who reported a common strategy classified as an EBP reported lower depressive and anxiety symptoms. In contrast, there was no evidence of an association between symptom levels and whether or not participants’ effective strategy was an EBP. Participants who reported the same strategy as both their common and effective strategy (29%) reported lower depressive symptoms than those whose common and effective strategies were different. Conclusions: Our findings highlight stressors that students are experiencing and ways they are coping during the COVID-19 crisis. We discuss how these findings can inform mental health promotion efforts and future research on coping with stressors.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://psyarxiv.com/6wj85/" target="_blank">Commonly reported problems and coping strategies during the COVID-19 crisis: A survey of graduate and professional students</a>
</div></li>
<li><strong>A metal ion orients mRNA to ensure accurate 2’-O ribosyl methylation of the first nucleotide of the SARS-CoV-2 genome</strong> -
<div>
The SARS-CoV-2 nsp16/nsp10 enzyme complex modifies the 2’-OH of the first transcribed nucleotide of the viral mRNA by covalently attaching a methyl group to it. The 2’-O methylation of the first nucleotide converts the status of mRNA cap from Cap-0 to Cap-1, and thus, helps the virus evade immune surveillance in the host cell. Here, we report two structures of nsp16/nsp10 representing pre- and post-release states of the RNA product (Cap-1). We observe overall widening of the enzyme upon product formation, and an inward twisting motion in the substrate binding region upon product release. These conformational changes reset the enzyme for the next round of catalysis. The structures also identify a unique binding mode and the importance of a divalent metal ion for 2’-O methylation. We also describe underlying structural basis for the perturbed enzymatic activity of a clinical variant of SARS-CoV-2, and a previous SARS-CoV outbreak strain.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.03.12.435174v1" target="_blank">A metal ion orients mRNA to ensure accurate 2’-O ribosyl methylation of the first nucleotide of the SARS-CoV-2 genome</a>
</div></li>
<li><strong>Google Trends as a method to predict new COVID-19 cases</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
In this paper, we develop a method that can detect and predict the emergence of new cases of COVID-19 at an early stage. With this method, we try to lay the empirical basis for the development of the model of digital monitoring and prediction of the occurrence of new cases of COVID-19 in Croatia, relying on the analytical tool Google Trends (GT). Results: In Croatia search activities using GT for terms such as “PCR +Covid”, “PCR + test”, and symptoms “cough + corona”, “pneumonia + corona”; “muscle pain + corona” correlate strongly with officially reported cases of the disease. Google Trends tools are suitable for predicting the emergence of new COVID-19 cases in Croatia, and that the data collected by this method correlate with official data. The benefit of this method is reliable estimates that can enable public health officials to prepare and better respond to the possible return of a pandemic in certain parts of the country. If a region experiences an early, sharp increase in Covid-19-like-illness Google searches, it may be possible to focus additional resources on that region to identify the etiology of the outbreak, providing extra medical capacity or raising local media awareness as necessary. Because the relative frequency of certain queries is highly correlated with the percentage of physician visits in which a patient presents with Covid-19 symptoms, this method can serve as an early alarm to predict the emergence of new cases of COVID-19 in the specific area in Croatia.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.03.12.21253452v1" target="_blank">Google Trends as a method to predict new COVID-19 cases</a>
</div></li>
<li><strong>COVID-19 vaccine hesitancy among undergraduate medical students: results from a nationwide survey in India</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
COVID-19 vaccine was launched in India on 16 January 2021, prioritizing health care workers which included medical students. We aimed to assess vaccine hesitancy and factors related to it among undergraduate medical students in India. An online questionnaire was filled by 1068 medical students across 22 states and union territories of India from 2 February to 7 March 2021. Vaccine hesitancy was found among 10.6%. Concern regarding vaccine safety and efficacy, hurried testing of vaccines prior to launch and lack of trust in government agencies predicted COVID-19 vaccine hesitancy. Risk perception regarding contracting COVID-19 vaccine reduced COVID-19 vaccine hesitancy as well as hesitation in participating in COVID-19 vaccine trials. Choosing between the two available vaccines (Covishield and Covaxin) was considered important by medical students both for themselves and their future patients. Covishield was preferred to Covaxin by students. Majority of those willing to take the COVID-19 vaccine felt that it was important for them to resume their clinical posting, face-to-face classes and get their personal life back on track. Around three-fourths medical students viewed that COVID-19 vaccine should be made mandatory for both health care workers and international travellers. Prior adult vaccination did not have an effect upon COVID-19 vaccine hesitancy. Targeted awareness campaigns, regulatory oversight of vaccine trials and public release of safety and efficacy data and trust building activities could further reduce COVID-19 vaccine hesitancy among medical students.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.03.12.21253444v1" target="_blank">COVID-19 vaccine hesitancy among undergraduate medical students: results from a nationwide survey in India</a>
</div></li>
<li><strong>Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice</strong> -
<div>
The emergence of SARS-CoV and SARS-CoV-2 in the 21st century highlights the need to develop universal vaccination strategies against the SARS-related Sarbecovirus subgenus. Using structure-guided chimeric spike designs and multiplexed immunizations, we demonstrate protection against SARS-CoV, SARS-CoV-2, and bat CoV (BtCoV) RsSHC014 challenge in highly vulnerable aged mice. Chimeric spike mRNAs containing N-terminal domain (NTD), and receptor binding domains (RBD) induced high levels of broadly protective neutralizing antibodies against three high-risk sarbecoviruses: SARS-CoV, RsSHC014, and WIV-1. In contrast, SARS-CoV-2 mRNA vaccination not only showed a 10 to &gt;500-fold reduction in neutralizing titers against heterologous sarbecovirus strains, but SARS-CoV challenge in mice resulted in breakthrough infection including measurable lung pathology. Importantly, chimeric spike mRNA vaccines efficiently neutralized both the D614G and the South African B.1.351 variants of concern despite some reduction in neutralization activity. Thus, multiplexed-chimeric spikes may provide a novel strategy to prevent pandemic and SARS-like zoonotic coronavirus infections, while revealing the limited efficacy of SARS-CoV-2 spike vaccines against other sarbecoviruses.
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2021.03.11.434872v1" target="_blank">Chimeric spike mRNA vaccines protect against sarbecovirus challenge in mice</a>
</div></li>
<li><strong>SARS-CoV-2 infection and risk of clinical sequelae during the post-acute phase: a retrospective cohort study</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Objective: Clinical sequelae have not been well characterized during the post-acute phase of SARS-CoV-2 among adults 18 to 65 years old, and this study sought to fill that gap by evaluating excess risk and relative hazards for developing incident clinical sequelae during the post-acute phase. Design: Retrospective cohort study including three propensity-matched groups. Setting: This study merged three data sources from a large United States health plan: a large national administrative claims database, an outpatient lab testing database, and an inpatient hospital admissions database. Participants: Individuals 18 to 65 years old with continuous health plan enrollment from January 2019 to date of SARS-CoV-2 diagnosis. Three comparator groups were identified and propensity-score matched to individuals infected with SARS-CoV-2: a 2020 comparator group, a historical 2019 comparator group and a historical comparator group with viral lower respiratory tract illness (vLRTI). Main outcome measures: Over 50 clinical sequelae during the post-acute phase (index date + 21 days) were ascertained using ICD-10 codes. Excess risk due to SARS-CoV-2 during the 4 months following the acute phase of illness and hazard ratios with 95% Bonferroni-corrected confidence intervals were calculated. Results: This study found 14% of adults ≤65 years of age who were infected with SARS-CoV-2 (n=193113) had at least one new clinical sequelae that required medical attention during the post-acute phase of illness. When considering risk for specific sequelae attributable to SARS-Cov-2 infection during the post-acute phase, clinical outcomes including chronic respiratory failure, cardiac arrythmia, hypercoagulability, encephalopathy, peripheral neuropathy, amnesia (memory difficulty), diabetes, liver test abnormalities, myocarditis, anxiety and fatigue were significantly elevated compared to the three propensity-matched comparator groups (2020, 2019, vLRTI). Significant risk differences due to SARS-CoV-2 infection ranged from 0.02 to 2.26 per 100 people and hazard ratios ranged from 1.24 to 25.65 when compared to the 2020 comparator group. Conclusions: Our results confirm excess risk for developing clinical sequelae due to SARS-CoV-2 during the post-acute phase, including specific types of sequelae less commonly seen among other viral illnesses. Although individuals who were older, had pre-existing conditions, and were hospitalized due to COVID-19 were at greatest excess risk, younger adults (≤50 years), adults who did not have pre-existing conditions or adults who were not hospitalized due to COVID-19 were still at elevated risk for developing new clinical sequelae. The elevated risk for incident sequelae during the post-acute phase is relevant for healthcare planning.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.03.12.21253448v1" target="_blank">SARS-CoV-2 infection and risk of clinical sequelae during the post-acute phase: a retrospective cohort study</a>
</div></li>
<li><strong>Delayed Start of the Respiratory Syncytial Virus Epidemic at the End of the 20/21 Northern Hemisphere Winter Season, Lyon, France</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The implementation of Non Pharmaceutical Interventions (NPI), triggered by the emergence of covid-19, decrease the RSV circulation. Data, from our ongoing surveillance; show a late introduction of RSV at the end of December and a 4 month delayed epidemic start without significant change in our NPI policy. This data indicates that RSV still have the potential to give a late season outbreak in northern hemisphere. RSV surveillance should be reinforced and RSV Pharmaceutical Interventions maintained for at risk neonate.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.03.12.21253446v1" target="_blank">Delayed Start of the Respiratory Syncytial Virus Epidemic at the End of the 20/21 Northern Hemisphere Winter Season, Lyon, France</a>
</div></li>
<li><strong>Sars-CoV-2 attack rate in reception and accommodation centres for asylum seekers: systematic review of outbreak media reports in Germany</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Objectives Despite concerns about the impact of the severe acute respiratory syndrome corona virus (Sars-CoV-2) in refugee camps, data on attack rates and effectiveness of containment measures are lacking. We aimed to (1) quantify the attack rate of Sars-CoV-2 during outbreaks in reception and accommodation centres in Germany, (2) assess differences in the attack rate based on containment measures, and (3) provide an overview of testing strategies, communication, conflicts, and protection measures for refugees with special needs. Methods Systematic web-based review of outbreak media reports (until June 2020) on confirmed Sars-CoV-2 cases in reception centers for asylum seekers in Germany using the google search engine. Reports were screened for pre-defined inclusion criteria and complemented by snowball searches. Data on facility name, location, confirmed cases, containment measures, communication, protection strategies, and conflicts was extracted for each outbreak and reporting date. Evidence synthesis: meta-analysis and negative binomial regression. Findings We identified 337 media reports on 101 Sars-CoV-2 outbreaks in 99 reception and accommodation centers in Germany. The pooled Sars-CoV-2 attack rate was 13.1% (95% confidence interval, CI: 9.8- 16.7). Outbreak sites implementing mass quarantine (n=76) showed higher rates (15.7; 95% CI: 11.6 - 20.2) compared to sites using conventional strategies (6.6; 95%CI: 3.1 - 11.2), yielding a rate ratio of 0.44 (95%CI: 0.27-0.72) adjusted for testing strategies, type and size of accommodation. Conflicts occurred in at least 11.8% of all outbreaks. Few sites reported specific measures to protect refugees with special needs. Conclusion Mass quarantine is associated with higher attack rates, and appears to be a counter-productive containment measure in overcrowded camps. Although further research with individual-level data is required to rule out residual confounding, reception centers and refugee camps should follow the available guidelines on Covid-19 response and refrain from mass quarantine if physical distancing cannot be guaranteed.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.03.12.21249641v1" target="_blank">Sars-CoV-2 attack rate in reception and accommodation centres for asylum seekers: systematic review of outbreak media reports in Germany</a>
</div></li>
<li><strong>Prevalence of COVID-19 in Iran: Results of the first survey of the Iranian COVID-19 Serological Surveillance program</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Abstract Background: This study aims to estimate the prevalence of COVID-19 in the general population of Iran. Methods: The target population was all Iranian people aged six years and older in the country. A stratified random sampling design was used to select 28,314 subjects from among the individuals registered in the electronic health record systems used in primary health care in Iran. Venous blood was taken from each participant and tested for the IgG antibody against COVID-19. The prevalence of COVID-19 was estimated at provincial and national levels after adjusting for the measurement error of the laboratory test, non-response bias, and sampling design. Results: Of the 28,314 Iranians selected, 11,256 (39.75%) participated in the study. Of these, 5406 (48.0%) were male, and 6851 (60.9%) lived in urban areas. The mean (standard deviation) participant age was 35.89 (18.61) years. The adjusted prevalence of COVID-19 until August 20, 2020 was estimated as 14.2% (95% uncertainty interval: 13.3%, 15.2%), which was equal to 11,958,346 (95% confidence interval: 11,211,011-12,746,776) individuals. The prevalence of infection was 14.6%, 13.8%, 16.6%, 11.7%, and 19.4% among men, women, urban population, rural population, and individuals 60 years of age and older, respectively. Ardabil, Golestan, and Khuzestan provinces had the highest prevalence, and Alborz, Hormozgan, and Kerman provinces had the lowest. Conclusions: Based on the study results, a large proportion of the Iranian population had not yet been infected by COVID-19. The observance of hygienic principles and social restrictions should therefore continue until the majority of the population has been vaccinated. Keywords: COVID-19, Seroprevalence, Survey, Nationwide, Population-based, Iran, IgG test
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.03.12.21253442v1" target="_blank">Prevalence of COVID-19 in Iran: Results of the first survey of the Iranian COVID-19 Serological Surveillance program</a>
</div></li>
<li><strong>Modelling, prediction and design of national COVID-19 lockdowns by stringency and duration</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
The implementation of lockdowns has been a key policy to curb the spread of COVID-19 and to keep under control the number of infections. However, quantitatively predicting in advance the effects of lockdowns based on their stringency and duration is a complex task, in turn making it difficult for governments to design effective strategies to stop the disease. Leveraging a novel mathematical “hybrid” approach, we propose a new epidemic model that is able to predict the future number of active cases and deaths when lockdowns with different stringency levels or durations are enforced. The key observation is that lockdown-induced modifications of social habits may not be captured by traditional mean-field compartmental models because these models assume uniformity of social interactions among the population, which fails during lockdown. Our model is able to capture the abrupt social habit changes caused by lockdowns. The results are validated on the data of Israel and Germany by predicting past lockdowns and providing predictions in alternative lockdown scenarios (different stringency and duration). The findings show that our model can effectively support the design of lockdown strategies by stringency and duration, and quantitatively forecast the course of the epidemic during lockdown.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.03.12.21253454v1" target="_blank">Modelling, prediction and design of national COVID-19 lockdowns by stringency and duration</a>
</div></li>
<li><strong>I was facilitating everybody else’s life. And mine had just ground to a halt: the COVID-19 pandemic and its impact on women in the UK</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
A growing body of research has highlighted the disproportionately negative impact of the COVID-19 pandemic on women globally. This paper contributes to this work by interrogating the lived realities of 64 women in the UK through semi-structured interviews, undertaken during the first and second periods of lockdown associated with COVID-19 in 2020. Categorising the data by theme and type of gendered disadvantage, this paper explores the normative and policy-imposed constraints experienced by women in 2020, highlighting the role that government can and should proactively play in attending to gender inequalities throughout its COVID-19 response.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.03.12.21253136v1" target="_blank">I was facilitating everybody else’s life. And mine had just ground to a halt: the COVID-19 pandemic and its impact on women in the UK</a>
</div></li>
<li><strong>A simplified SARS-CoV-2 pseudovirus neutralization assay</strong> -
<div>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
COVID-19 is an ongoing pandemic caused by the highly infectious coronavirus SARS-CoV-2 that is engaging worldwide scientific research to find a timely and effective eradication strategy. Great efforts have been put into anti-COVID-19 vaccine generation in an effort to protect the world population and block SARS-CoV-2 spread. To validate the protective efficacy of the vaccination campaign and effectively control the pandemy, it is necessary to quantify the neutralizing antibodies induction by vaccination, since they have been established to be a correlate of protection. In this work a SARS-CoV-2 pseudovirus neutralization assay, based on a replication incompetent lentivirus expressing an adapted form of CoV-2 S protein and an ACE2/TMPRSS2 stably expressing cell line, have been minimized in term of protocol steps without loss of accuracy. The goal of the present simplified neutralization system is to improve SARS-CoV-2 vaccination campaign by means of an easy and accessible approach to be performed in any medical laboratory, maintaining the sensitivity and quantitative reliability of classical serum neutralization assays. Further this assay can be easily adapted to different coronaviruses variants by simply modifying the pseudotyping vector.
</p>
</div>
<div class="article-link article-html-link">
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.03.12.21253435v1" target="_blank">A simplified SARS-CoV-2 pseudovirus neutralization assay</a>
</div></li>
</ul>
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Clinical Study in the Treatment of Patients With COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: Molixan;   Drug: Placebo<br/><b>Sponsor</b>:   Pharma VAM<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Diagnostic Performance of the ID Now™ COVID-19 Screening Test Versus Simplexa™ COVID-19 Direct Assay</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Diagnostic Test: ID Now™ COVID-19 Screening Test<br/><b>Sponsor</b>:   Groupe Hospitalier Paris Saint Joseph<br/><b>Active, not recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: Melatonin;   Drug: Placebo<br/><b>Sponsors</b>:   State University of New York at Buffalo;   National Center for Advancing Translational Science (NCATS)<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19</strong> - <b>Condition</b>:   COVID-19<br/><b>Interventions</b>:   Drug: Brilacidin;   Drug: Placebo;   Drug: Standard of Care (SoC)<br/><b>Sponsor</b>:   Innovation Pharmaceuticals, Inc.<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>DCI COVID-19 Surveillance Project</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Diagnostic Test: SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection<br/><b>Sponsors</b>:   Temple University;   Dialysis Clinic, Inc.<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Biological: VIR-7831 (Gen1);   Biological: VIR-7831 (Gen2)<br/><b>Sponsors</b>:   Vir Biotechnology, Inc.;   GlaxoSmithKline<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Corticosteroids for COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Prednisone;   Device: Point of Care testing device for C-reactive protein<br/><b>Sponsor</b>:   University of Alberta<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Effects of Telerehabilitation After Discharge in COVID-19 Survivors</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Other: Telerehabilitation<br/><b>Sponsor</b>:   Hacettepe University<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Biological: Bamlanivimab;   Other: Standard of Care<br/><b>Sponsors</b>:   Fraser Health;   Fraser Health Authrority Department of Evaluation and Research Services;   Surrey Memorial Hospital Foundation;   University of British Columbia;   Centre for Health Evaluation and Outcome Sciences;   BC Support Unit;   Abcellera;   Surrey Memorial Hospital Clinical Research Unit<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy of Adaptogens in Patients With Long COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Dietary Supplement: ADAPT-232 oral solution;   Other: Placebo oral solution<br/><b>Sponsors</b>:   Swedish Herbal Institute AB;   National Family Medicine Training Centre, Georgia;   Tbilisi State Medical University;   Phytomed AB<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Law Enforcement Professionals With Risk Factors for Severity</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Biological: Adsorbed SARS-CoV-2 (inactivated) vaccine<br/><b>Sponsors</b>:   Fundação de Medicina Tropical Dr. Heitor Vieira Dourado;   Butantan Institute<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Vaccination of Immunodeficient Persons (COVAXID)</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Biological: Comirnaty (COVID-19, mRNA vaccine)<br/><b>Sponsors</b>:   Karolinska University Hospital;   Karolinska Institutet<br/><b>Recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico</strong> - <b>Condition</b>:   Covid19<br/><b>Intervention</b>:   Dietary Supplement: Vitamin D3<br/><b>Sponsor</b>:   University of Guadalajara<br/><b>Completed</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Dietary Supplements for COVID-19</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Drug: Vitamin D3 50,000 IU;   Dietary Supplement: Vitamin C/Zinc;   Dietary Supplement: Vitamin K2/D;   Other: Microcrystalline Cellulose Capsule;   Other: Medium Chain Triglyceride Oil<br/><b>Sponsors</b>:   The Canadian College of Naturopathic Medicine;   Ottawa Hospital Research Institute<br/><b>Not yet recruiting</b></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients</strong> - <b>Condition</b>:   Covid19<br/><b>Interventions</b>:   Device: Carragelose;   Device: NaCl<br/><b>Sponsors</b>:   Marinomed Biotech AG;   Austian Research Promotion Agency<br/><b>Recruiting</b></p></li>
</ul>
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
<ul>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>ARB-Based Combination Therapy for the Clinical Management of Hypertension and Hypertension-Related Comorbidities: A Spotlight on Their Use in COVID-19 Patients</strong> - Essential hypertension is the most common cardiovascular (CV) risk factor, being primarily involved in the pathogenesis of CV disease and mortality worldwide. Given the high prevalence and growing incidence of this clinical condition in the general population in both high and low-income countries, antihypertensive drug therapies are frequently prescribed in different hypertension-related CV diseases and comorbidities. Among these conditions, evidence are available demonstrating the clinical…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 vaccination and antirheumatic therapy</strong> - The COVID-19 vaccination will be the largest vaccination programme in the history of the NHS. Patients on immunosuppressive therapy will be amongst the earliest to be vaccinated. Some evidence indicates immunosuppressive therapy inhibits humoral response to the influenza, pneumococcal and hepatitis B vaccines. The degree to which this will translate to impaired COVID-19 vaccine responses is unclear. Other evidence suggests withholding methotrexate for two weeks post vaccination may improve…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 pneumonia: do not leave the corticosteroids behind!</strong> - The host inflammatory response is critical in the progression of lung injuries in patients with SARS-CoV-2. Corticosteroids (CS) have been widely used as immunomodulating agents, but the right timing, dosage and type of molecule are unknown. In fact, the early use of CS could facilitate the viral replication but late administration may not prevent the alveolar damage. Nevertheless, a short administration of high doses of CS in the early stage of the inflammatory phase resulted in favorable…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Targeting mesenchymal stem cell therapy for severe pneumonia patients</strong> - Pneumonia is the inflammation of the lungs and it is the world’s leading cause of death for children under 5 years of age. The latest coronavirus disease 2019 (COVID-19) virus is a prominent culprit to severe pneumonia. With the pandemic running rampant for the past year, more than 1590000 deaths has occurred worldwide up to December 2020 and are substantially attributable to severe pneumonia and induced cytokine storm. Effective therapeutic approaches in addition to the vaccines and drugs under…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2</strong> - Drug repurposing is a rapid approach to identify therapeutics for the treatment of emerging infectious diseases such as COVID-19. To address the urgent need for treatment options, we carried out a quantitative high-throughput screen using a SARS-CoV-2 cytopathic assay with a compound collection of 8,810 approved and investigational drugs, mechanism-based bioactive compounds, and natural products. Three hundred and nineteen compounds with anti-SARS-CoV-2 activities were identified and confirmed,…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19</strong> - The COVID-19 pandemic has caused a global health crisis, with no specific antiviral to treat the infection and the absence of a suitable vaccine to prevent it. While some individuals contracting the SARS-CoV-2 infection exhibit a well coordinated immune response and recover, others display a dysfunctional immune response leading to serious complications including ARDS, sepsis, MOF; associated with morbidity and mortality. Studies revealed that in patients with a dysfunctional immune response,…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface</strong> - COVID-19 is a severe acute respiratory disease caused by SARS-CoV-2, a new recently emerged sarbecovirus. This virus uses the human ACE2 enzyme as receptor for cell entry, recognizing it with the receptor binding domain (RBD) of the S1 subunit of the viral spike protein. We present the use of phage display to select anti-SARS-CoV-2 spike antibodies from the human naïve antibody gene libraries HAL9/10 and subsequent identification of 309 unique fully human antibodies against S1. 17 antibodies are…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers</strong> - The circulating metabolome provides a snapshot of the physiological state of the organism responding to pathogenic challenges. Here we report alterations in the plasma metabolome reflecting the clinical presentation of COVID-19 patients with mild (ambulatory) diseases, moderate disease (radiologically confirmed pneumonitis, hospitalization and oxygen therapy), and critical disease (in intensive care). This analysis revealed major disease- and stage-associated shifts in the metabolome, meaning…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19</strong> - Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is at present an emerging global public health crisis. Angiotensin converting enzyme 2 (ACE2) and trans-membrane protease serine 2 (TMPRSS2) are the two major host factors that contribute to the virulence of SARS-CoV-2 and pathogenesis of coronavirus disease-19 (COVID-19). Transmission of SARS-CoV-2 from animal to human is considered a rare event that necessarily requires strong evolutionary adaptations. Till date no other…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Exploring dynamics and network analysis of spike glycoprotein of SARS-COV-2</strong> - The ongoing pandemic caused by coronavirus SARS-COV-2 continues to rage with devastating consequences on human health and global economy. The spike glycoprotein on the surface of coronavirus mediates its entry into host cells and is the target of all current antibody design efforts to neutralize the virus. The glycan shield of the spike helps the virus to evade the human immune response by providing a thick sugar-coated barrier against any antibody. To study the dynamic motion of glycans in the…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation</strong> - The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became a pandemic, resulting in an exponentially increased mortality globally and scientists all over the world are struggling to find suitable solutions to combat it. Multiple repurposed drugs have already been in several clinical trials or recently completed. However, none of them shows any promising effect in combating COVID-19. Therefore, developing an effective drug is an unmet…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease</strong> - The outbreak of a new coronavirus (SARS-CoV-2), which is responsible for the COVID-19 disease and is spreading rapidly around the world, urgently requires effective therapeutic treatments. In this context, drug repurposing represents a valuable strategy, as it enables accelerating the identification of drug candidates with already known safety profiles, possibly aiding in the late stages of clinical evaluation. Moreover, therapeutic treatments based on drugs with beneficial multi-target…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Effect of Supervision Waivers on Practice: A Survey of Massachusetts Nurse Practitioners During the COVID-19 Pandemic</strong> - CONCLUSIONS: Temporary removal of state-level practice barriers alone is not sufficient to achieve immediate full scope of practice for NPs. The successful implementation of modernized scope of practice laws may require a collective effort to revise organizational and payer policies accordingly.</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Disinfectants Used in Stomatology and SARS-CoV-2 Infection</strong> - Effective disinfection is a basic procedure in medical facilities, including those conducting dental surgeries, where treatments for tissue discontinuity are also performed, as it is an important element of infection prevention. Disinfectants used in dentistry and dental and maxillofacial surgery include both inorganic (hydrogen peroxide, sodium chlorite-hypochlorite) and organic compounds (ethanol, isopropanol, peracetic acid, chlorhexidine, eugenol). Various mechanisms of action of…</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology</strong> - Since chloroquine (CQ) and hydroxychloroquine (HCQ) can inhibit the invasion and proliferation of SARS-CoV-2 in cultured cells, the repurposing of these antimalarial drugs was considered a promising strategy for treatment and prevention of COVID-19. However, despite promising preliminary findings, many clinical trials showed neither significant therapeutic nor prophylactic benefits of CQ and HCQ against COVID-19. Here, we aim to answer the question of why these drugs are not effective against…</p></li>
</ul>
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Sars-CoV-2 vaccine antigens</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU318283136">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>SARS-COV-2 BINDING PROTEINS</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU318004130">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Compositions and methods for detecting SARS-CoV-2 spike protein</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU317343760">link</a></p></li>
<li><strong>Aronia-Mundspray</strong> -
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Anordnung zum Versprühen einer Substanz in die menschliche Mundhöhle und/oder in den Rachen, dadurch gekennzeichnet, dass die Anordnung eine Sprühflasche mit einer Substanz aufweist, die wenigstens Aroniasaft und eine Alkoholkomponente aufweist.
</p>
<ul>
<li><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE319581893">link</a></li>
</ul></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>基于水疱性口炎病毒载体的新型冠状病毒嵌合重组疫苗及其制备方法与应用</strong> - 本发明公开了基于水疱性口炎病毒载体的新型冠状病毒嵌合重组疫苗及其制备方法与应用。该重组疫苗的活性成分为重组病毒rVSV‑SARS‑CoV/2‑RBD，为将水疱性口炎病毒的糖蛋白G替换为嵌合囊膜蛋白S后得到的病毒；所述嵌合囊膜蛋白S为将SARS‑CoV囊膜蛋白S的RBD替换为SARS‑CoV‑2囊膜蛋白S的RBD后得到的蛋白；所述SARS‑CoV囊膜蛋白S的RBD的氨基酸序列为SARS‑CoV囊膜蛋白S氨基酸序列的第315‑536位；所述SARS‑CoV‑2囊膜蛋白S的RBD的氨基酸序列为SARS‑CoV‑2囊膜蛋白S氨基酸序列的第319‑541位。该重组病毒对新冠病毒的疫苗研制具有重要意义。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN319598609">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>一种3-羟基丁酰化修饰蛋白质药物及其制备方法和应用</strong> - 本发明涉及医药技术领域，公开了一种3‑羟基丁酰化修饰蛋白质药物（例如抗体）及其制备方法和应用，特别是一种3‑羟基丁酰化修饰抗体及其制备方法和应用。发明人经过大量实验发现，3‑羟基丁酸及其类似物修饰蛋白质药物（例如抗体）后，可以显著提高蛋白质药物的热稳定性、对蛋白酶水解的抗性，降低蛋白质药物的等电点，并显著延长其在受试者体内的半衰期，进而提高其药效。修饰后所得蛋白质药物在科研和临床方面具有广阔的应用前景和较高的商业价值。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN318140486">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>新冠病毒重组融合蛋白、其制备方法和应用</strong> - 本发明提供一种新冠病毒重组融合蛋白、其制备方法和应用。本发明通过对新冠病毒S和N重组融合蛋白的基因序列进行设计，选择最优的片段进行整合，再通过人源HEK293细胞系统重组表达融合蛋白，经过纯化后对融合蛋白的分子量、纯度进行检测，最后利用融合蛋白制成新冠病毒抗体胶体金检测试纸条/试剂盒。与单独使用S蛋白或N蛋白制备的胶体金检测试纸条相比，该重组融合蛋白制备的胶体金检测试纸条具有更高的灵敏度和更低的漏检率。此外，本发明提供的新冠病毒重组融合蛋白可广泛应用于不同平台技术的新冠抗体检测试剂盒开发，如胶体金、荧光免疫层析、化学发光和酶联免疫等。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN318140491">link</a></p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Atemluft-Desinfektionsvorrichtung und Atemschutzmaske</strong> -
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
Atemluft-Desinfektionsvorrichtung mit einem am Körper eines Lebewesens (2) tragbaren Gehäuse (32), aufweisend:</p></li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">eine im Gehäuse (32) ausgebildete frei durchströmbare Atemluft-Bestrahlungskammer (33), die frei von den Strömungswiderstand erhöhenden Einbauten oder Umlenkabschnitten ist, und die an einem Ende (34.1) der Atemluft-Bestrahlungskammer (33) eine im Strömungsweg der Nase und/oder dem Mund des Lebewesens (2) zugewandte erste Durchtrittsöffnung (35.1) aufweist und an einem anderen Ende (34.2) der Atemluft-Bestrahlungskammer (33) eine im Strömungsweg von der Nase und/oder von dem Mund des Lebewesens (2) abgewandte zweite Durchtrittsöffnung (35.2) aufweist, wobei die Atemluft-Bestrahlungskammer (33) von wenigstens einer UV-reflektierenden Kammer-Innenwand (36) begrenzt ist, die aus einem wärmeleitenden Material besteht,</li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">wenigstens eine im Gehäuse (32) angeordnete, in die Atemluft-Bestrahlungskammer (33) einstrahlende UV-LED-Einheit (31, 31.1, 31.2), die ausgebildet und eingerichtet ist, den Innenraum der Atemluft-Bestrahlungskammer (33) mit UV-Strahlen vollständig zu beaufschlagen, und</li>
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">wenigstens einen sich außerhalb der Atemluft-Bestrahlungskammer (33) erstreckenden Kühlkörper (37), der thermisch sowohl an die wenigstens eine UV-LED-Einheit (31, 31.1, 31.2), als auch an die aus dem wärmeleitenden Material bestehende Kammer-Innenwand (36, 39, 40) angekoppelt ist.</p></li>
</ul>
<img alt="embedded image" id="EMI-D00000"/>
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
<ul>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=DE319581907">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>制备重组新型冠状病毒Spike蛋白的方法</strong> - 本发明提供了一种制备重组新型冠状病毒Spike蛋白的方法。本发明首先提供以下多肽作为信号肽在制备重组新型冠状病毒Spike蛋白中的应用：SEQ ID No. 10所示氨基酸序列组成的多肽。本发明采用特定信号肽，构建含有编码重组新型冠状病毒Spike蛋白的多核苷酸的表达载体，转染哺乳动物细胞以分泌表达重组新型冠状病毒Spike蛋白，可显著提高Spike蛋白在HEK293细胞中的分泌表达水平。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN319598598">link</a></p></li>
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>新型冠状病毒抗体检测试剂盒及其制备方法与应用</strong> - 本发明提供一种新型冠状病毒抗体检测试剂盒及其制备方法与应用。所述试剂盒包括：IgG结合分子，抗IgM抗体，荧光标记的新型冠状病毒S1蛋白，荧光标记的新型冠状病毒N蛋白，S1蛋白的hIgG抗体阳性标准品，N蛋白的hIgG抗体阳性标准品，S1蛋白的hIgM抗体阳性标准品，N蛋白的hIgM抗体阳性标准品，阴性对照hIgG抗体样品，阴性对照hIgM抗体样品；其中，所述IgG结合分子与抗IgM抗体负载于不同粒径的纳米颗粒上。本发明的试剂盒用于新型冠状病毒抗体检测，可在1‑2h内快速完成血清中新型冠状病毒中和性抗体的检测，待检样品用量少，特异性强，灵敏度高，重复性好，操作简单，实验室要求低以及安全性高。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN319598593">link</a></p></li>
</ul>
<script>AOS.init();</script></body></html>